Edwards Lifesciences (NYSE:EW) PT Raised to $91.00 at Evercore ISI

Edwards Lifesciences (NYSE:EW) had its price target increased by equities researchers at Evercore ISI from $89.00 to $91.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has an “in-line” rating on the medical research company’s stock. Evercore ISI’s price objective would indicate a potential upside of 0.76% from the company’s previous close.

Several other research analysts have also weighed in on the company. Stifel Nicolaus increased their target price on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Friday, April 26th. Deutsche Bank Aktiengesellschaft raised Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $86.00 to $103.00 in a research note on Tuesday, May 14th. StockNews.com raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Thursday, June 27th. The Goldman Sachs Group assumed coverage on shares of Edwards Lifesciences in a report on Thursday, May 30th. They issued a “buy” rating and a $107.00 price target on the stock. Finally, Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a research note on Friday, April 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $95.18.

Edwards Lifesciences Trading Up 0.1 %

EW traded up $0.06 during midday trading on Tuesday, hitting $90.31. The company’s stock had a trading volume of 327,257 shares, compared to its average volume of 3,446,568. The firm has a market cap of $54.42 billion, a P/E ratio of 38.93, a PEG ratio of 3.38 and a beta of 1.11. Edwards Lifesciences has a 52-week low of $60.57 and a 52-week high of $96.12. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The firm has a 50-day moving average price of $87.85 and a two-hundred day moving average price of $85.37.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. On average, research analysts anticipate that Edwards Lifesciences will post 2.77 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the completion of the sale, the director now owns 4,486 shares of the company’s stock, valued at $414,596.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $92.42, for a total value of $2,712,527.00. Following the completion of the transaction, the director now directly owns 4,486 shares in the company, valued at $414,596.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the sale, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 119,849 shares of company stock valued at $10,579,038. Insiders own 1.27% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of EW. Nordea Investment Management AB boosted its position in Edwards Lifesciences by 1,224.1% during the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after acquiring an additional 1,488,791 shares during the period. Telos Capital Management Inc. increased its stake in Edwards Lifesciences by 158.2% during the 4th quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock valued at $6,970,000 after buying an additional 56,000 shares during the period. Arlington Trust Co LLC raised its position in shares of Edwards Lifesciences by 5,092.4% during the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock worth $938,000 after buying an additional 12,069 shares in the last quarter. HealthInvest Partners AB acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $1,587,000. Finally, Ninety One UK Ltd increased its stake in shares of Edwards Lifesciences by 2,740.5% during the fourth quarter. Ninety One UK Ltd now owns 498,029 shares of the medical research company’s stock valued at $37,975,000 after acquiring an additional 480,496 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.